Navigation Links
Rosetta Genomics Reaches Settlement Agreement with Sanra Laboratories in Connection with Previous Sale of Parkway Clinical Laboratories
Date:4/18/2013

PHILADELPHIA and REHOVOT, Israel, April 18, 2013 /PRNewswire/ -- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced that the Company has negotiated a settlement with Sanra Laboratories ("Sanra") in connection with the previous sale of Parkway Clinical Laboratories ("Parkway") by Rosetta Genomics to Sanra.  Under the agreement, Sanra will undertake their best efforts to pay Rosetta Genomics $625,000, in addition to all sums previously paid by them, for total consideration of all their obligations according to the stock purchase agreement entered into in May 2009, of which amount Sanra has already paid $10,000 as an upfront payment. 

On July 22, 2008, through Rosetta Genomics Inc., the Company purchased all of the shares of Parkway Clinical Laboratories, Inc., a privately held Pennsylvania corporation owning a CLIA-certified laboratory.  With its CLIA certification, Parkway helped Rosetta Genomics to obtain CLIA certification for its laboratory in Philadelphia, Pennsylvania.  Parkway remained an indirect, wholly-owned subsidiary until May 18, 2009, when the Company sold Parkway to Sanra for up to $2.5 million, to be paid as a fixed percentage from the revenues over six years. 

About miRview® Testing Services
miRview® assays are a series of microRNA-based diagnostic testing services offered by Rosetta Genomics. miRview® mets² accurately identifies the primary tumor type in primary and metastatic cancer including cancer of unknown or uncertain primary (CUP). miRview® meso diagnoses mesothelioma, a cancer connected to asbestos exposure.  miRview® lung accurately identifies the four main subtypes of lung cancer using small amounts of tumor cells. miRview® kidney accurately classifies the four most common kidney tumors: clear cell renal cell carcinoma (RCC), papillary RCC, chromophobe RCC and oncocytoma.  miRview® assays are designed to provide objective diagnostic data; it is the treating physician's responsibility to diagnose and administer the appropriate treatment.  In the U.S. alone, Rosetta Genomics estimates that 200,000 patients a year may benefit from the miRview® mets² assay, 60,000 from miRview® meso, 65,000 from miRview® kidney and 226,000 patients from miRview® lung. The Company's assays are offered directly by Rosetta Genomics in the U.S., and through distributors around the world. For more information, please visit www.mirviewdx.com. Parties interested in ordering the test can contact Rosetta Genomics at (215) 382-9000 ext. 309.

About Rosetta Genomics
Rosetta develops and commercializes a full range of microRNA-based molecular diagnostics.  Founded in 2000, Rosetta's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools. Rosetta's miRview® testing services are commercially available through its Philadelphia-based CAP-accredited, CLIA-certified lab.  Frost & Sullivan recognized Rosetta Genomics with the 2012 North American Next Generation Diagnostics Entrepreneurial Company of the Year Award.

Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta's future expectations, plans and prospects, including without limitation, statements relating to Rosetta's  receipt of funds from Sanra, Rosetta's development or commercialization of molecular diagnostics, the market acceptance of Rosetta's miRview® assays, particularly miRview® mets2, Rosetta's capitalization of its microRNA platform, Rosetta's patent position and Rosetta's development of personalized medicine products and services constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2012 as filed with the SEC. In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

Company Contact: 
Rosetta Genomics                                         
Ken Berlin , President & CEO                                 
(215) 382-9000, ext. 326                                         
investors@rosettagenomics.com

Investor Contacts:                          
LHA                                      
Anne Marie Fields
(212) 838-3777
afields@lhai.com
or
Bruce Voss
(310) 691-7100
bvoss@lhai.com


'/>"/>
SOURCE Rosetta Genomics Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Rosetta Genomics Announces Poster Presentations at AACR Annual Meeting 2013
2. Rosetta Genomics Expands Management Team, Laboratory Capacities and Commercial Operations
3. Rosetta Genomics Receives 2012 North American Entrepreneurial Company of the Year Award by Frost & Sullivan
4. Rosetta Genomics Announces Closing of Public Offering of 5.5 Million Ordinary Shares
5. Rosetta Genomics Pays Off Secured Loan and Reclaims Unencumbered Rights to All Assets
6. Real Time Genomics and Omicia Partner on a Platform for Integrated Genomic Analysis for Childhood Disease
7. Venter Institute-Led Team Recovers and Sequences Genome of Periodontal Pathogen from Biofilm in Hospital Sink using Single-Cell Genomics
8. Squished bug genomics: Insect goo aids biodiversity research
9. BGI-Shenzhen Completes Acquisition of Complete Genomics
10. Genomics Data Management Leader Annai Systems Offers Shortcut to Analysis
11. Real Time Genomics Announces Formation of its Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... GAITHERSBURG, Md. , Jan. 19, 2017 ... Inc., a privately-held immunotherapeutics company targeting infectious diseases, ... for the merger of PharmAthene and Altimmune in ... Venture Fund, HealthCap, Truffle Capital and Redmont Capital. ... diversified immunotherapeutics company with four clinical stage and ...
(Date:1/19/2017)... 2017 AquaBounty Technologies, Inc. (AIM: ABTU; NASDAQ: ... aquaculture and a majority-owned subsidiary of Intrexon Corporation (NYSE: ... the listing of its common shares on the NASDAQ ... "AquaBounty,s listing on NASDAQ represents an important ... to the U.S. markets as we advance plans for ...
(Date:1/19/2017)... , ... January 18, 2017 , ... ... tech innovators, engineers, and scientists from around the world, was today awarded the ... awards program is based entirely on merit and decided upon by a dedicated ...
(Date:1/19/2017)... ... January 19, 2017 , ... DaVita Clinical Research ... drug and device development, and Prism Clinical Research , a leader in ... Verified Clinical Trials (VCT) has been selected by both companies as ...
Breaking Biology Technology:
(Date:1/19/2017)... , Jan. 19, 2017 ... user experience and security for consumer electronics, and ... payment processing systems and cybersecurity solutions, today announced ... enterprises and financial institutions worldwide to bolster security ... the end-to-end secure user authentication platforms they offer, ...
(Date:1/12/2017)... -- New research undertaken by Fit Small Business has ... were simply asked which office technology had they not used ... issue.  Insights on what will be key features ... and industry leaders including Penelope Trunk , Martin ... Some of these findings included; ...
(Date:1/6/2017)... Jan. 5, 2017  SomaLogic announced today that ... Alliance" established by iCarbonX, the China ... a "Global Digital Health Ecosystem that can define ... of individual,s biological, behavioral and psychological data, the ... the companies, SomaLogic will provide proteomics data and ...
Breaking Biology News(10 mins):